Cross-Sector entity
GSK is the most frequent co-covered peer, appearing in 3 of the 3 tracked stories. That works out to roughly 0.1 stories per week across a 160-day span. The busiest single day carried 2. Coverage clusters in clinical-trial, which accounts for 1 of those 3, with the remainder spread across 2 other categories.
3 verified stories tracked
Last mentioned: Aug 4, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
GSK is the most frequent co-covered peer, appearing in 3 of the 3 tracked stories. That works out to roughly 0.1 stories per week across a 160-day span. The busiest single day carried 2. Coverage clusters in clinical-trial, which accounts for 1 of those 3, with the remainder spread across 2 other categories. Each carries 2 original sources on average. This profile follows 3 Cross-Sector stories mentioning WVE-006 across the period from February 26, 2026 to August 4, 2026.
Computed from the 3 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering WVE-006. Shared-story counts are live from our verified record — not editorial picks.
Wave Life Sciences presented Phase I data for WVE-007, an siRNA targeting Activin E, demonstrating up to 88% serum reduction sustained for over 7.5 months. The INLIGHT Phase IIa trial is now enrolling 160 patients across four cohorts, with a focus on BMI 35–50 and type 2 diabetes status, aiming to validate the RNA editing platform's potential for durable obesity treatment.
Wave Life Sciences' WVE-007, a novel siRNA silencing Activin E, demonstrated a 16.5% improvement in visceral fat-to-muscle ratio in Phase I, outpacing existing therapies and offering a potential solution for the 70% of GLP-1 users who discontinue within a year. With enrollment underway in the INLIGHT Phase IIa trial, the 175 million individuals with obesity in the U.S. and Europe may soon have a longer-lasting, disease-modifying option.
Source: Motley Fool Transcribing (us) · fool.com
Wave Life Sciences and Collegium Pharmaceutical reported full-year 2025 results, highlighting a transformative period for RNA editing and commercial pain management. Wave's clinical progress in AATD and DMD remains a primary valuation driver, while Collegium continues to optimize its specialized portfolio through strategic acquisitions.
